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Based on exclusion criteria in the landmark NINDS-rtPA trial, current expert consensus guidelines preclude the use of intravenous
recombinant tissue plasminogen activator (IV rtPA) in acute ischemic stroke (AIS) patients with intracranial neoplasm. There are
only 3 published cases of administration of IV rtPA to AIS patients with intracranial neoplasms in the literature. Two of these
published cases involved malignant brain parenchymal lesions discovered only after rtPA was inadvertently given, and one of
these cases was associated with hemorrhage within the tumor. In this paper, we report two cases of administration of IV rtPA in
AIS patients with intracranial neoplasms observed on neuroimaging prior to IV rtPA administration. In both cases, the tumor
was outside of the brain parenchyma. The ﬁrst case was an acoustic schwannoma and the second a falcine meningioma. Neither
case was associated with intratumoral hemorrhage as of at least one week following IV rtPA treatment. More published cases are
deﬁnitelywarranted,butourexperiencewiththesetwocasessuggeststhatadministrationofIVrtPAtoAISpatientsinthepresence
of extraparenchymal brain tumors may not necessarily precipitate intra-tumoral bleeding and thereby worsen clinical outcomes.
1.Introduction
Fifteen years after Food and Drug Administration approval
ofintravenousrecombinanttissueplasminogenactivator(IV
rtPA) for treatment of acute ischemic stroke (AIS), only
a substantial minority of AIS patients (<2 % )o fs t r o k e s
receive this proven therapy [1]. While several barriers exist
to increasing utilization of rtPA among AIS patients [1],
there are many patients who do not receive this eﬃcacious
treatment on the basis of product labeling derived from the
landmark NINDS-rtPA trial exclusion criteria [2]. For the
most part, the selection of NINDS-rtPA exclusion was based
on theoretical concerns and it is increasingly being shown
that utilizing rtPA in patients with some of these criteria may
not necessarily result in unfavorable outcomes [3]. One of
these exclusion criteria, presence of intracranial neoplasm, is
considered a contraindication to IV rtPA use AIS in because
of increased intracranial bleeding risk [4]. However, the
actualriskofsystemicthrombolysis-precipitated intracranial
bleeding in AIS patients is unknown, and as far as we are
aware, there are only 3 cases of rtPA use in AIS patients with
intracranial neoplasm in the literature [5–7]. We report our
experience with the administration of IV rtPA to two AIS
patients with intracranial tumors and review the literature.
2.Case1
A 77-year-old man developed sudden onset left upper, and
lower extremity weakness. His past medical history included
hypertension, hyperlipidemia and type 2 diabetes. He had
experienced two prior strokes (the more recent one two
years prior to this presentation) which resulted in residual
mild left hemiparesis. On admission, blood pressure was
146/50mmHg, and pulse was 56 beats per minute and
regular. Neurological examination revealed ﬂaccid left lower
extremityweaknessaﬀectingproximalanddistalmuscles.He
wasunabletowalk.NationalInstitutesofHealthStrokeScale
Score (NIHSSS) was 4. Noncontrast head CT demonstrated
a hyperdense right anterior cerebral artery (ACA) and a het-
erogeneous lobulated mass within the left cerebellopontine
angle measuring 3.3 × 1.3cm. There was mild mass eﬀect
on the adjacent pons (Figure 1(a)). CT angiogram showed2 Case Reports in Medicine
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Figure 1: (a) Non-contrast head CT showing a heterogeneous
lobulated mass within the left cerebellopontine angle (arrow). (b)
Followup brain MRI in same patient 3 days later.
an abrupt cut oﬀ of the right ACA, and CT perfusion showed
a defect in the corresponding ACA territory. He was given IV
rtPA 5mg IV bolus followed by 44.5mg IV, based on weight.
Initially, his deﬁcits improved, but then returned eight hours
later with greater intensity. Brain MRIperformed3 days later
did not demonstrate bleeding either in the cerebellopontine
angle mass or elsewhere (Figure 1(b)). He was eventually
discharged to an acute rehabilitation facility. Three months
later, he had mild residual weakness of the left leg, and he
was again able to walk with a cane.
3.Case2
A 74-year-old woman arrived after a fall witnessed by
family members. Past history included type 2 diabetes,
hypertension, and hyperlipidemia. Initial blood pressure
165/77mmHg, and pulse was 83 beats per minute and
irregularly irregular. Neurological evaluation revealed right
gaze deviation, ﬂattening of the left nasolabial fold, and
dysarthria, ﬂaccid left arm with no strength, weakness of left
leg (2/5 strength), and left-sided neglect. NIHSSS was 13.
Noncontrast head CT demonstrated a hyperdense right mid-
dle cerebral artery, bilateral basal ganglia calciﬁcation, and
an occipital falcine mass (Figure 2(a)). She received 62mg of
IV rtPA based on her weight 90 minutes after stroke onset.
ShortlyaftercompletionofrtPAinfusion,thepatientbecame
morelethargicandcomplainedofaworseningheadache.She
was intubated for airway protection due to her decreased
level of consciousness and diminished gag reﬂex. A repeat
head CT at the time showed no evidence of hemorrhage.
At 48 hours after treatment, her NIHSS was 15 and she was
able to follow one step commands on her right side, but still
had profound neglect and ﬂaccid arm weakness. She was still
able to move right leg within the plane of gravity. Head CT
performedat36hoursdemonstratedincreasingedemainthe
distributionofthelargerightMCAinfarct,withmidlineshift
measuring 5mm, but there was no evidence of hemorrhagic
transformation or intratumor bleeding (Figure 2(b)).
4. Discussion
We report two cases of safe administration of IV t-PA in
acute ischemic stroke patients with intracranial neoplasm. In
both cases, the tumor was outside of the brain parenchyma.
The ﬁrst case was possibly an acoustic schwannoma, and the
second a falcine meningioma. Neither case was associated
with intratumor hemorrhage.
As already noted, there are extremely few cases of IV
t-PAuseinAISpatientswithintracranialneoplasmsreported
in the literature. Two of these cases involved initially un-
detected malignant intracranial neoplasms, while the
remaining one involved a benign intracranial neoplasm seen
priortotreatment.Forinstance,a57-year-oldmanwithaleft
temporal lobe glioblastoma multiforme (GBM) (subse-
quently diagnosed after magnetic resonance imaging and
neurosurgery days later) was inadvertently given IV rtPA
after a normal initial head CT. There was no evidence of
bloodbythatMRIorfollow-upheadCT.Thepatientbecame
asymptomatic on the seventh day [5]. However, in another
case of malignant brain neoplasm, an 80-year-old man, also
inadvertently given IV rtPA for a presumed AIS, worsened
twenty hours after receiving rtPA, and CT revealed a left
temporoparietal hemorrhage.Follow-upMRI2monthslater
demonstrated a GBM in the hemorrhage bed [6]. More
similar to the two cases we have presented in this paper,
thatis, presumedbenign intracranialneoplasms observed on
neuroimaging prior to IV rtPA, therapy, is the case of a 60-
year-old woman, who presented with AIS and was noted on
head CT to have a 2cm frontal meningioma. After receiving
IV rtPA the neurological deﬁcits improved. Brain magneticCase Reports in Medicine 3
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Figure 2: (a) Initial head CT showing parafalcine mass (arrow). (b)
Head CT 36 hours after t-PA.
resonance imaging, 3 days after onset, showed an acute
infarction at the right basal ganglion without hemorrhage
and no bleeding within the meningioma. Modiﬁed Rankin
Scale was 1 at 1-month and 0 at 6-month follow-up [7].
Admittedly, the number of reported cases of rtPA
treatment for AIS in patients with intracranial neoplasms
is far too small to make any deﬁnitive inferences, but there
is a suggestion, based on previous cases as well as our
current report, that the presence of a presumably benign
intracranial neoplasm seen on neuroimaging prior to IV
rtPAtreatmentmaynotnecessarilycontributetounfavorable
imaging or clinical outcomes in AIS and perhaps should not
preclude treatment. Further supportive evidence of possibly
little harm from using intravenous thrombolysis among
vascular disease patients with benign intracranial neoplasm
may be seen among the few reported cases of i.v. rtPA
use in nonstroke patients [8, 9]. Three patients with acute
myocardial infarction and benign intracranial neoplasms
havebeenreportedintheliterature,twoofthesepatientshad
coexisting meningiomas, while one of them had a pituitary
adenoma [8, 9]. Posttreatment head CT scans did not show
any evidence of intracranial or intratumor bleeding [8, 9].
The implied low risk of harm in the aforementioned cases
of I.V. rtPA therapy in the context of benign intracranial
neoplasm notwithstanding, more cases are needed to bolster
the premise that the presence of such tumors should not
deter treatment in otherwise eligible AIS patients.
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